GlaxoSmithKline's study of Promacta does not provide "robust" evidence that the proposed drug works better than placebos in reducing bleeding in patients with chronic idiopathic thrombocytopenic purpura, the FDA announced Wednesday. GSK and partner Ligand Pharmaceuticals declined to comment on the findings, which are set to be reviewed by an expert panel Friday.

Related Summaries